APLS logo

Apellis Pharmaceuticals (APLS)

Profile

Full Name

Apellis Pharmaceuticals, Inc.

Ticker Symbol

APLS

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

November 9, 2017

Indexes

Not included

Website

http://apellis.com

Employees

705

Key Details

Price

$19.42(+3.35%)

Market cap

$2.44B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$781.37M(+97.02% YoY)

Annual EPS

-$1.60(+64.04% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$19.42
APLS price is $19.42

30-Day Relative Volume

0.90
APLS 30-day relative volume is 0.90

Price Performance

Price Today change

+3.35%
APLS price is up +3.35% today

Price YTD change

-39.14%
APLS price is down -39.14% since January 1st

Price 1-year change

-65.15%
APLS price is down -65.15% year-on-year

Price 3-year change

-63.65%
APLS price is down -63.65% over the past 3 years

Price Range

Price All-time high

$94.75
APLS price is currently -79.50% below its historical high of $94.75

Price 3-year low

$17.48
APLS price is currently +11.07% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$2.44B
APLS market capitalization is $2.44 billion

Market cap 3-year change

-57.15%
APLS market capitalization is down -57.15% over the past 3 years

Market cap All-time high

$10.93B
APLS market capitalization is currently -77.70% below its historical high of $10.93 billion

Market cap sector rank

84.72%
APLS market capitalization is higher than 84.72% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+3.48%
APLS shares outstanding is up +3.48% year-on-year

Shares Outstanding 3-Year Change

+17.88%
APLS shares outstanding is up +17.88% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.02
APLS beta is 1.02

200-day SMA

$31.29
APLS price is currently -37.93% below its 200-day simple moving average

50-day SMA

$25.21
APLS price is currently -22.98% below its 50-day simple moving average

RSI

32.06
APLS 14-day relative strength index is 32.06

Volume

0.90
APLS 30-day relative volume is 0.90

ATR

$1.70
APLS average true range is $1.70

10-day Historical Volatility

89.77%
APLS 10-day historical volatility is 89.77%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$781.37M
APLS annual revenue is $781.37 million

Revenue Analysts estimate

$865.23M
APLS annual revenue is currently -9.69% lower than the consensus analysts' forecast

Revenue 1-year change

+97.02%
APLS annual revenue is up +97.02% year-on-year

Revenue Sector rank

78.61%
APLS annual revenue is higher than 78.61% of companies in Healthcare sector

EPS

EPS

-$1.60
APLS annual earnings per share is -$1.60

EPS Analysts estimate

-$1.02
APLS annual earnings per share is currently +56.49% higher than the consensus analysts' forecast

EPS 1-year change

+64.04%
APLS annual earnings per share is up +64.04% year-on-year

EPS Sector rank

43.68%
APLS annual earnings per share is higher than 43.68% of companies in Healthcare sector

Profit

Gross profit

$663.64M
APLS annual gross profit is $663.64 million

Gross margin

84.93%
APLS annual gross profit margin is 84.93%

Operating profit

-$164.98M
APLS annual operating income is -$164.98 million

Operating margin

-21.11%
APLS annual operating profit margin is -21.11%

Net income

-$197.88M
APLS annual net profit is -$197.88 million

Net margin

-25.32%
APLS annual net profit margin is -25.32%

Expenses

Total expenses

$946.35M
APLS annual total expenses is $946.35 million

Operating expenses

$828.62M
APLS annual total operating expenses is $828.62 million

Cost of goods sold

$117.72M
APLS annual cost of goods sold is $117.72 million

Selling, general & administrative expenses

$501.05M
APLS annual SGA is $501.05 million

Depreciation and amortization

$1.80M
APLS annual depreciation & amortization is $1.80 million

Interest expense

$40.39M
APLS annual interest expense is $40.39 million

Income tax

$1.16M
APLS annual income tax is $1.16 million

EBIT & EBITDA

EBIT

-$156.32M
APLS annual earnings before interest & taxes is -$156.32 million

EBITDA

-$154.53M
APLS annual EBITDA is -$154.53 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$885.05M
APLS annual total assets is $885.05 million

Non current assets

$96.10M
APLS annual long term assets is $96.10 million

Current assets

$788.95M
APLS annual total current assets is $788.95 million

Cash and cash equivalents

$411.29M
APLS annual cash & cash equivalents is $411.29 million

Accounts receivable

$264.93M
APLS annual accounts receivable is $264.93 million

Inventory

$81.40M
APLS annual inventory is $81.40 million

Liabilities

Total liabilities

$656.51M
APLS annual total liabilities is $656.51 million

Long term liabilities

$471.00M
APLS annual total long term liabilities is $471.00 million

Current liabilities

$185.51M
APLS annual total current liabilities is $185.51 million

Accounts payable

$38.57M
APLS annual accounts payable is $38.57 million

Debt

Total debt

$469.78M
APLS annual total debt is $469.78 million

Total debt 1-year change

+323.5%
APLS annual total debt is up +323.5% year-on-year

Long term debt

$463.03M
APLS annual long term debt is $463.03 million

Short term debt

$6.75M
APLS annual short term debt is $6.75 million

Equity & Capital

Shareholders equity

$228.54M
APLS annual stockholders equity is $228.54 million

Book value

$228.54M
APLS annual book value is $228.54 million

Retained earnings

-$3.04B
APLS annual retained earnings is -$3.04 billion

Working capital

$603.45M
APLS annual working capital is $603.45 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$87.87M
APLS annual cash flow from operations is -$87.87 million

Cash from operations 1-year change

+85.23%
APLS annual cash flow from operations is up +85.23% year-on-year

Cash from investing

-$403.00K
APLS annual cash flow from investing activities is -$403.00 thousand

Cash from investing 1-year change

+40.21%
APLS annual cash flow from investing activities is up +40.21% year-on-year

Cash from financing

$149.24M
APLS annual cash flow from financing activities is $149.24 million

Cash from financing 1-year change

-62.17%
APLS annual cash flow from financing activities is down -62.17% year-on-year

CAPEX

CAPEX

$403.00K
APLS annual capital expenditures is $403.00 thousand

CAPEX 1-year change

-47.87%
APLS annual capital expenditures is down -47.87% year-on-year

Free Cash Flow

Free cash flow

-$88.27M
APLS annual free cash flow is -$88.27 million

Free cash flow 1-year change

+85.18%
APLS annual free cash flow is up +85.18% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

84.93%
APLS annual gross profit margin is 84.93%

Operating margin

-21.11%
APLS annual operating profit margin is -21.11%

Net margin

-25.32%
APLS annual net profit margin is -25.32%

ROA & ROE

ROA

-23.64%
APLS annual return on assets is -23.64%

ROE

-93.55%
APLS annual return on equity is -93.55%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
APLS price to earnings ratio value is unknown

PE ratio Sector rank

-
APLS price to earnings ratio is unknown

PB Ratio

PB ratio

10.67
APLS price to book ratio is 10.67

PB ratio Sector rank

93.59%
APLS price to book ratio is higher than 93.59% of companies in Healthcare sector

PS Ratio

PS ratio

3.12
APLS price to sales ratio is 3.12

PS ratio Sector rank

53.46%
APLS price to sales ratio is higher than 53.46% of companies in Healthcare sector

Enterprise value

Enterprise value

$2.50B
APLS enterprise value is $2.50 billion

Enterprise value Sector rank

84.09%
APLS enterprise value is higher than 84.09% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-16.15
APLS EV/EBITDA is -16.15

EV/EBITDA Sector rank

7.55%
APLS EV/EBITDA is higher than 7.55% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.25
APLS annual current ratio is 4.25

Quick ratio

3.81
APLS annual quick ratio is 3.81

Leverage

Debt to equity

1.98
APLS annual debt to equity ratio is 1.98

Interest coverage ratio

-3.87
APLS annual interest coverage ratio is -3.87

Risk & Stability

Piotroski F-Score

3
APLS piotroski f-score is 3

Altman Z-Score

-1.46
APLS altman z-score is -1.46

Analyst ratings

Recent major analysts updates

Oct 16, 24 William Blair
Outperform
Oct 16, 24 Scotiabank
Sector Perform
Sep 24, 24 Wells Fargo
Equal-Weight
Sep 23, 24 Baird
Outperform
Sep 20, 24 Needham
Buy
Sep 20, 24 Mizuho
Neutral
Sep 13, 24 JP Morgan
Overweight
Aug 13, 24 JP Morgan
Overweight
Aug 9, 24 Wedbush
Neutral
Aug 9, 24 UBS
Buy

Institutional Ownership

Similar stocks

VCYT logo
Veracyte (VCYT)
ACAD logo
ACADIA Pharmaceuticals (ACAD)
XENE logo
Xenon Pharmaceuticals (XENE)
VKTX logo
Viking Therapeutics (VKTX)
AGL logo
agilon health (AGL)
ALVO logo
Alvotech (ALVO)
SRRK logo
Scholar Rock Holding (SRRK)
CRNX logo
Crinetics Pharmaceuticals (CRNX)
PTGX logo
Protagonist Therapeutics (PTGX)
  • What is the ticker symbol for Apellis Pharmaceuticals?
  • Does Apellis Pharmaceuticals pay dividends?
  • What sector is Apellis Pharmaceuticals in?
  • What industry is Apellis Pharmaceuticals in?
  • What country is Apellis Pharmaceuticals based in?
  • When did Apellis Pharmaceuticals go public?
  • Is Apellis Pharmaceuticals in the S&P 500?
  • Is Apellis Pharmaceuticals in the NASDAQ 100?
  • Is Apellis Pharmaceuticals in the Dow Jones?
  • When was Apellis Pharmaceuticals's last earnings report?
  • When does Apellis Pharmaceuticals report earnings?
  • Should I buy Apellis Pharmaceuticals stock now?

What is the ticker symbol for Apellis Pharmaceuticals?

The ticker symbol for Apellis Pharmaceuticals is NASDAQ:APLS

Does Apellis Pharmaceuticals pay dividends?

No, Apellis Pharmaceuticals does not pay dividends

What sector is Apellis Pharmaceuticals in?

Apellis Pharmaceuticals is in the Healthcare sector

What industry is Apellis Pharmaceuticals in?

Apellis Pharmaceuticals is in the Biotechnology industry

What country is Apellis Pharmaceuticals based in?

Apellis Pharmaceuticals is headquartered in United States

When did Apellis Pharmaceuticals go public?

Apellis Pharmaceuticals's initial public offering (IPO) was on November 9, 2017

Is Apellis Pharmaceuticals in the S&P 500?

No, Apellis Pharmaceuticals is not included in the S&P 500 index

Is Apellis Pharmaceuticals in the NASDAQ 100?

No, Apellis Pharmaceuticals is not included in the NASDAQ 100 index

Is Apellis Pharmaceuticals in the Dow Jones?

No, Apellis Pharmaceuticals is not included in the Dow Jones index

When was Apellis Pharmaceuticals's last earnings report?

Apellis Pharmaceuticals's most recent earnings report was on Feb 28, 2025

When does Apellis Pharmaceuticals report earnings?

The next expected earnings date for Apellis Pharmaceuticals is May 7, 2025

Should I buy Apellis Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page